Scpharmaceuticals Inc. (NASDAQ: SCPH)Q1 2025 Revenue Conference May 14th, 2025, 4:30pm
Company participants
William Thorpe – Investor Relations
John Tucker – Chief Executive Officer
Steve Parsons – Senior Vice President of Commercial
Rachel Nokes – Chief Financial Officer
Participants in conference calls
Roanna Ruiz -Leerink Partners
Stacy Ku -TD Cowen
Douglas Zao-HC Wainwright
Chase Knickerbocker – Craig Hulm
operator
Hello. At this point, all participants are in listening only mode. A question and answer session will be followed by prepared statements from management. [Operator Instructions] Today’s conference call is recorded as a reminder.
I would like to hand over the meeting to investor Will Thorpe to cover forward-looking statements. thank you.
William Thorpe
Thank you, operator. Before we begin our revenue call this afternoon, we would like to highlight our next forward-looking statement. All statements relating to this conference call other than historical facts are forward-looking statements within the meaning of the federal securities law, including, but not limited to, the anticipated future financial results of SCPharmaceuticals, business expectations and planning, the continued commercialization and marketing of Furoscix, the expansion of potential labels, and the increased increase in the decline in the penetration of Furoscix’s diving style, continued commercialization, and the approval of continued cash expansion. Distributed as out-of-pocket costs decrease and estimated COG reductions decrease.
This term generally uses similar expressions such as forecast, believe, anticipate, anticipate, intend, target, project or other similar expressions to guidance, confidence, target, project and other similar expressions to identify such forward-looking statements. These forward-looking statements do not guarantee future performance. It may involve certain risks and uncertainties and other important factors that may affect Scpharmaceuticals’ business, financial position and other operating outcomes, and may address other factors. These include risk factors and other qualifications included in Scpharmaceuticals annual report on Form 10-K, but included in the quarterly report on Form 10-Q
